Ductal Breast Carcinoma In Situ
42
5
13
22
Key Insights
Highlights
Success Rate
92% trial completion (above average)
Published Results
14 trials with published results (33%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
4.8%
2 terminated out of 42 trials
91.7%
+5.2% vs benchmark
5%
2 trials in Phase 3/4
64%
14 of 22 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 22 completed trials
Clinical Trials (42)
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer
The PREDICT Registry:
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants
Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
Prospective Pilot Study of Robot-assisted Nipple Sparing Mastectomy (RNSM)
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast Cancer
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
Caloric Restriction in Treating Patients With Stage 0-I Breast Cancer Undergoing Surgery and Radiation Therapy
Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast Cancer
The PROMISE Study: Duavee in Women With DCIS
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast
Soy Isoflavones Supplementation in Treating Women at High Risk For or With Breast Cancer
Accelerated Partial Breast Radiation Therapy Using High-Dose Rate Brachytherapy in Treating Patients With Early Stage Breast Cancer After Surgery